<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Epigenetic therapies, including DNA methyltransferase and <z:chebi fb="0" ids="15358">histone</z:chebi> deacetylase inhibitors, represent important new treatment modalities in <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e>, but their mechanism of action remains unknown </plain></SENT>
<SENT sid="1" pm="."><plain>We reasoned that up-regulation of epigenetically silenced <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> antigens may induce an immunologically mediated antitumor response and contribute to their clinical activity </plain></SENT>
<SENT sid="2" pm="."><plain>In this study, we demonstrate that <z:chebi fb="0" ids="2038">azacitidine</z:chebi> (AZA) and <z:chebi fb="0" ids="9925">sodium valproate</z:chebi> (VPA) up-regulate expression of <z:hpo ids='HP_0002861'>melanoma</z:hpo>-associated antigens (MAGE antigens) on <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) and <z:mp ids='MP_0009440'>myeloma</z:mp> cell lines </plain></SENT>
<SENT sid="3" pm="."><plain>In separate studies, we observed that prior exposure to AZA/VPA increased recognition of <z:mp ids='MP_0009440'>myeloma</z:mp> cell lines by a MAGE-specific CD8(+) cytotoxic T-lymphocyte (CTL) clone </plain></SENT>
<SENT sid="4" pm="."><plain>We therefore measured CTL responses to MAGE antigens in 21 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> or <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> treated with AZA/VPA </plain></SENT>
<SENT sid="5" pm="."><plain>CTL responses to MAGE antigens were documented in only 1 patient before therapy; however, treatment with AZA/VPA induced a CTL response in 10 patients </plain></SENT>
<SENT sid="6" pm="."><plain>Eight of the 11 patients with circulating MAGE CTLs achieved a major clinical response after AZA/VPA therapy </plain></SENT>
<SENT sid="7" pm="."><plain>This is the first demonstration of a MAGE-specific CTL response in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Furthermore, it appears that epigenetic therapies have the capacity to induce a CTL response to MAGE antigens in vivo that may contribute to their clinical activity in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
</text></document>